Stockscreener 앱 받기
29.93
1.49%
0.44
시간 외 거래:
29.93
전일 마감가:
$29.49
열려 있는:
$29.65
하루 거래량:
273.59K
Relative Volume:
0.72
시가총액:
$1.81B
수익:
-
순이익/손실:
$-118.12M
주가수익비율:
-13.13
EPS:
-2.2802
순현금흐름:
$-82.63M
1주 성능:
+7.05%
1개월 성능:
+13.20%
6개월 성능:
+58.28%
1년 성능:
+57.44%
1일 변동 폭
$29.11
$30.25
1주일 범위
$27.35
$31.27
52주 변동 폭
$16.00
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
29.93 | 1.78B | 0 | -118.12M | -82.63M | -2.2802 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | JP Morgan | Overweight |
| 2025-08-27 | 개시 | Needham | Buy |
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
Oculis Holding (OCS) Stock Analysis Report | Financials & Insights - Benzinga
How Investors May Respond To Oculis (OCS) Q1 Loss, Governance Moves And Guggenheim Pipeline Spotlight - simplywall.st
OCS Stock Price, Quote & Chart | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
OCS Initiates Coverage On Guggenheim -- Price Target Announced a - GuruFocus
Oculis Holding AG Warrants (OCSAW) Live Share Price, Invest From India - INDmoney
Guggenheim Initiates Oculis Holding at Buy With $75 Price Target - marketscreener.com
OCS Technical Analysis & Stock Price Forecast - Intellectia AI
Guggenheim initiates Oculis stock with buy rating on DME treatment potential - Investing.com Nigeria
Guggenheim initiates coverage of Oculis Holding (OCS) with buy recommendation - MSN
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength? - MSN
Oculis FDA SPA Sharpens Privosegtor Phase 3 Path And Investor Focus - Sahm
OCS Maintained by JP Morgan -- Price Target Raised to $42.00 - GuruFocus
(OCS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Oculis Holding AG (OCS) reports Q1 loss, lags revenue estimates - MSN
TradingKey - TradingKey
Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility - TipRanks
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors - marketscreener.com
Oculis (NASDAQ: OCS) clears AGM, adds new director and treasury share capacity - Stock Titan
Oculis Holding Ag Announces Board and Committee Changes - marketscreener.com
Oculis's global DME consensus study identifies critical gaps in care - Eyes On Eyecare
HC Wainwright Issues Positive Forecast for Oculis Earnings - MarketBeat
Oculis birtir niðurstöður aðalfundar 2026 og tilkynnir um kjör Gregory D. Perry í stjórn félagsins - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright raises Oculis stock price target to $47 on trial progress - Investing.com UK
Q1 Earnings Forecast for Oculis Issued By HC Wainwright - MarketBeat
OCS: All agenda items passed, with strong financials and major clinical milestones on track - TradingView
Oculis Releases First Quarter 2026 Financial Results, Provides Company Update - VisionMonday.com
Is Oculis (OCS) Turning Regulatory Momentum In Ophthalmology Into A Durable Competitive Edge? - simplywall.st
FDA agrees to special protocol assessment for Oculis’s phase 3 ON trial - Eyes On Eyecare
Oculis Reports Q1 2026 Financial Results and Provides Company Update - The Manila Times
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Oculis Holding AG (NASDAQ:OCS) Q1 Earnings Miss Overshadowed by Key Pipeline Catalysts - ChartMill
Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results - TipRanks
Oculis (NASDAQ: OCS) advances late-stage eye pipeline with CHF 222m cash - Stock Titan
Press Release: Oculis Reports Q1 2026 Financial Results and Provides Company Update - Moomoo
Weighing Oculis Holding (NasdaqGM:OCS) Rich P/B Against DCF Upside After Strong Multi Year Share Gains - Yahoo Finance
Oculis stock gains after FDA trial design agreement By Investing.com - Investing.com Australia
Oculis stock gains after FDA trial design agreement - Investing.com India
Number of shareholders of Oculis Holding AG – NASDAQ:OCS - TradingView
Oculis secures FDA agreement on trial design for Privosegtor in optic neuritis treatment - Pluang
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial - The Manila Times
Oculis Holding AG Receives FDA Special Protocol Assessment for Privosegtor's PIONEER-1 Trial in Optic Neuritis Treatment - Quiver Quantitative
Oculis gets FDA agreement on study design for optic neuritis drug - Stock Titan
(OCS) Risk Channels and Responsive Allocation - Stock Traders Daily
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting - The Manila Times
60% go untreated in DME; Oculis nears June eye-drop data - Stock Titan
Oculis (OCS) to Release Earnings on Monday - MarketBeat
Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes - TipRanks
H.C. Wainwright raises Oculis stock price target to $44 on trial progress - Investing.com
Gildi lifeyrissjodur Makes New Investment in Oculis Holding AG $OCS - MarketBeat
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):